Tirzepatide

Weight Loss & Metabolism

Tirzepatide's defining research application — the only dual GIP/GLP-1 agonist among approved weight-loss peptides.

Appetite suppression

Suppresses appetite through combined GIP and GLP-1 receptor activation, a broader signal than single-pathway GLP-1 drugs.

Blood sugar regulation

Stimulates glucose-dependent insulin release via dual receptor activation, improving blood sugar control beyond GLP-1 alone.

Cardiovascular risk reduction

Improves blood pressure and cholesterol markers as a downstream effect of significant weight loss.

Fat loss

Drives fat loss through appetite suppression and improved metabolic signaling across two hormone pathways at once.

Improved insulin sensitivity

The added GIP receptor activation appears to improve insulin sensitivity more than GLP-1 activation alone.

Weight loss

Produced the greatest average weight loss of any approved GLP-1-class drug in head-to-head trials against semaglutide.